Login to Your Account

Biogen Idec Excels on Tecfidera Launch

By Catherine Shaffer
Staff Writer

Friday, July 26, 2013

Biogen Idec Inc., of Weston, Mass., blasted consensus sales estimates for multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) out of the water, turning in $192 million in its second quarter earnings, compared to the $75 million expected by the street. The company's total revenues were $1.7 billion for the second quarter, up 21 percent over the second quarter of 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription